ORGANON GETS FIRST EUROPEAN MARKETING APPROVAL FOR REMERON.
The Dutch regulatory approval triggers a mutual recognition procedure involving other European countries.
Remeron SolTab, an antidepressant that incorporates CIMA's OraSolv(R) fast-dissolve drug delivery system with Organon's active drug ingredient, mirtazapine, received U.S. regulatory approval in January 2001 and became commercially available in this year's first quarter.
Remeron, which has been available in the U.S. since 1996 in solid oral dosage form, has been Organon's best-selling U.S. product. CIMA is Organon's exclusive supplier of Remeron SolTab.
In a separate development, the company announced that earlier in July, CIMA was included in the Russell 3000(R) Index, a stock market index composed of the 3,000 largest stocks in the U.S. equity market ranked by market capitalization as of May 31.
About CIMA LABS
CIMA develops and manufactures prescription and over-the-counter products for pharmaceutical companies based upon its proprietary, fast-dissolve drug delivery technologies, OraSolv(R) and DuraSolv(TM). CIMA formulates a pharmaceutical company's active drug ingredient into a new, orally disintegrating dosage form that dissolves quickly in the mouth without chewing or the need for water. Taste masking agents may be used with the company's fast-dissolve technologies to prevent or minimize the unpleasant taste associated with many active drug ingredients. CIMA currently manufactures five pharmaceutical brands utilizing its OraSolv and DuraSolv technologies: three prescription and two over-the-counter.
For more information, call 952/947-8700. >TX CORIXA GET $1 MILLION MILESTONE PAYMENT FROM JAPAN TOBACCO >TX Corixa Corporation (Nasdaq: CRXA), Seattle, a developer of immunotherapeutics, has received a $1 million milestone payment as a result of its research collaboration and license agreement with the pharmaceutical division of Japan Tobacco Inc. (JT) to support Corixa's development of therapeutic lung cancer vaccines. The milestone was achieved following JT's selection of a Corixa antigen for further development.
This is the first milestone payment Corixa has received under the terms of a 1999 agreement with JT, which provides JT with certain rights to develop vaccine products containing Corixa's novel lung cancer antigens, including antigens formulated using Corixa's microsphere delivery system and proprietary adjuvant technologies. The agreement provides JT with exclusive rights to vaccine products aimed at treating lung cancer and potentially other solid tumors in humans, principally in Japan and North America, as well as co-exclusive rights with Zambon Group spa in China. Under the agreement, Corixa may receive a total of over $40 million in license fees, research funding and milestone payments based upon successful clinical and commercial progress.
"Our achievement of this milestone represents continued advancement of our lung cancer antigen discovery program," said Steven Gillis, Ph.D., chairman and chief executive officer of Corixa. "We are pleased with the progress of our collaboration with JT and hopeful that our discovery efforts will be used in lung cancer therapeutic products worldwide."
Corixa is a developer of immunotherapeutics with a commitment to treating and preventing autoimmune diseases, cancer and infectious diseases by understanding and directing the immune system. Corixa is focused on immunotherapeutic products and has a broad technology platform enabling both fully integrated vaccine design and the use of its separate, proprietary product components on a standalone basis. Corixa currently has 16 programs in clinical development and 22 programs in preclinical development, including its most advanced product candidate, Bexxar(TM), a monoclonal antibody conjugated to a radioisotope.
The company partners with numerous developers and marketers of pharmaceuticals, targeting products that are Powered by Corixa(TM) technology with the goal of making its potential products available to patients around the world. Corixa was founded in 1994 and is headquartered in Seattle, Washington, with additional operations in Hamilton, Montana and South San Francisco, California.
For more information, visit http://www.corixa.com or call 1.877.4CORIXA or 1.877.426.7492.
|Printer friendly Cite/link Email Feedback|
|Comment:||ORGANON GETS FIRST EUROPEAN MARKETING APPROVAL FOR REMERON.|
|Date:||Sep 1, 2001|
|Previous Article:||ID BIOMEDICAL INITIATES STREPTAVAX CLINICAL TRIAL.|
|Next Article:||U.K. HOSPITAL TREATS CANCER PATIENTS WITH SMARTBEAM IMRT.|